Although our results confirm this clinical concern, they suggest that only a pronounced and/or prolonged intake of APAP would be able to hamper the immune response to anti-PD-1/PD-L1 agents in patients with advanced NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.